KÜÇÜK HÜCRELİ VE KÜÇÜK HÜCRELİ OLMAYAN AKCİĞER KANSERLERİNDE ROL OYNAYAN MİRNA’LARIN BİYOİNFORMATİK ANALİZLERLE KARŞILAŞTIRILMASI

Öz

Amaç: Akciğer kanseri, dünya çapında karsinomla ilişkili ölümlerin önemli bir nedenidir. Küçük hücreli ve küçük hücreli olmayan 2 ana akciğer kanseri türü bulunmaktadır. İyi prognozun elde edilmesi, hedefe yönelik tedavinin geliştirilmesi ve potansiyel biyobelirteçleri belirlenmesi amacıyla yeni yöntemler bulmak, akciğer kanserinin klinik etkinliğini geliştirilmesi için büyük önem taşımaktadır. Çalışmanın amacı 2 alt tipte farklı ifade olan miRNA’ları bularak patogenezi ve potansiyel moleküler belirteçlerini incelemektir. Gereç ve Yöntem: miRNA verisi içeren GSE19945 ve GSE135918 nolu veri seti GEO veri tabanından indirilmiştir. GEO2R çevrimiçi analiz aracı ile P<0.05 ve log kat değişimi |(FC)|≥ 1 alınarak analiz edilmiştir. Farklı ifade edilen miRNA’ların hedef genleri tanımlanmıştır. Cytoscape PPI kullanılarak ağ görselleştirme ve modül tanımlaması yapılmıştır. miRNA hedef genlerinden 3 adet seçilerek genlerin validasyonu akciğer kanseri hücre hattı A549'da yapılmıştır. Sonuç ve Tartışma: 17 ifadesi azalan ve 2 ifadesi artan ortak miRNA’lar arasında hsa-miR-1249, hsa-miR-326, hsa-let-7c, hsa-miR-199a-5p, hsa-miR-940, hsa-miR-139-3p, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-455-5p, hsa-miR-146b-5p,hsa-miR-152hsa-miR-133b, hsa-miR-498, hsa-miR-199b-5p, hsa-miR-140-3p, hsa-miR-203 ve hsa-miR-139-5p yer almaktadır. miRNA’ların moleküler fonksiyonlarının ve sinyal yollarının tanımlanması, 2 kanser tipinin moleküler mekanizmalarının mevcut anlayışını derinleştirebilir ve, tedavi seçeneklerinin geliştirilmesine katkıda bulunabilir.

Anahtar Kelimeler

• Akciğer kanseri
• biyoinformatik analiz
• küçük hücreli akciğer kanseri
• küçük hücreli olmayan akciğer kanseri
• miRNA

Destekleyen Kurum

TÜBİTAK, Uşak Üniversitesi BAP

Proje Numarası

1919B012218259 , 2024/LP001

Teşekkür

2209A proje kapsamında desteklenmiştir. TÜBİTAK ve Uşak Ünveristesine teşekkür ederiz.

THE COMPARISON OF MICRORNAS INVOLVED IN SMALL CELL LUNG CANCER AND NON-SMALL CELL LUNG CANCER THROUGH BIOINFORMATICS ANALYSES

Öz

Objective: Lung cancer is a major cause of cancer-related deaths worldwide. There are two main types of lung cancer, small cell and non-small cell. Finding new methods for achieving a good prognosis, developing targeted therapy and identifying potential biomarkers is crucial for improving the clinical efficacy of lung cancer. The aim of this study was to investigate the pathogenesis and potential molecular markers by finding differentially expressed miRNAs in 2 subtypes of lung cancer. Materials and Methods: The datasets GSE19945 and GSE135918 containing miRNA data were downloaded from the GEO database. Analyzed with GEO2R online analysis tool with P<0.05 and log fold change |(FC)|≥ 1. Target genes of differentially expressed miRNAs have been identified. Network visualisation and module identification were performed using Cytoscape PPI. Three of the miRNA target genes were selected and validation of the genes was performed in the non-small cell lung cancer cell line A549. Results and discussion: 17 common miRNAs with decreased expression and 2 with increased expression include hsa-miR-1249, hsa-miR-326, hsa-let-7c, hsa-miR-199a-5p, hsa-miR-940, hsa-miR-139-3p, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-455-5p, hsa-miR-146b-5p,hsa-miR-152hsa-miR-133b, hsa-miR-498, hsa-miR-199b-5p, hsa-miR-140-3p, hsa-miR-203 and hsa-miR-139-5p. Defining the molecular functions and signaling pathways of miRNAs may deepen the current understanding of the molecular mechanisms of the 2 cancer types and contribute to the development of treatment options.

Anahtar Kelimeler

• Bioinformatics analysis
• lung cancer
• microRNA
• non-small cell lung cancer
• small cell lung cancer

Proje Numarası

1919B012218259 , 2024/LP001

Kaynakça

1. 1. Zappa, C., Mousa, S.A. (2016). Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research, 5(3), 288-300. [CrossRef]
2. 2. Xie, D., Marks, R., Zhang, M., Jiang, G., Jatoi, A., Garces, Y.I., Mansfield, A., Molina, J., Yang, P. (2015). Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. Journal of Thoracic Oncology, 10(8), 1213-1220. [CrossRef]
3. 3. Waqar, S.N., Morgensztern, D. (2017). Treatment advances in small cell lung cancer (SCLC). Pharmacology & Therapeutics, 180, 16-23. [CrossRef]
4. 4. Woodman, C., Vundu, G., George, A., Wilson, C.M. (2021). Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in Cancer Biology, 69, 349-364. [CrossRef]
5. 5. Misra, P., Singh, S. (2019). Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective. Cancer Medicine, 8(5), 1976-1995. [CrossRef]
6. 6. Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L. (2019). Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal For Clinicians, 69(5), 363-385. [CrossRef]
7. 7. Ettinger, D.S., Wood, D.E., Aggarwal, C., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., Bruno, D. S., Chang, J.Y., Chirieac, L.R., D'Amico, T.A., Dilling, T.J., Dobelbower, M., Gettinger, S., Govindan, R., Gubens, M.A., Hennon, M., Horn, L., Lackner, R.P., Lanuti, M., Leal, T.A., Lin, J., Loo, B.W., Martins, R.G., Otterson, G.A., Patel, S.P., Reckamp, K.L., Riely, G.J., Schild, S.E., Shapiro, T.A., Stevenson, J., Swanson, S.J., Tauer, K.W., Yang, S.C., Gregory, K., Hughes, M. (2019). NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 17(12), 1464-1472. [CrossRef]
8. 8. Udhaya Kumar, S., Thirumal Kumar, D., Bithia, R., Sankar, S., Magesh, R., Sidenna, M., George Priya Doss, C., Zayed, H. (2020). Analysis of differentially expressed genes and molecular pathways in familial hypercholesterolemia involved in atherosclerosis: A systematic and bioinformatics approach. Frontiers in Genetics, 11, 734. [CrossRef]

9. 9. Wan, J., Jiang, S., Jiang, Y., Ma, W., Wang, X., He, Z., Wang, X., Cui, R. (2020). Data mining and expression analysis of differential lncRNA ADAMTS9-AS1 in prostate cancer. Frontiers in Genetics, 10, 1377. [CrossRef]
10. 10. Fu, D., Zhang, B., Yang, L., Huang, S., Xin, W. (2020). Development of an immune-related risk signature for predicting prognosis in lung squamous cell carcinoma. Frontiers in Genetics, 11, 978. [CrossRef]
11. 11. Udhaya Kumar, S., Thirumal Kumar, D., Siva, R., George Priya Doss, C., Younes, S., Younes, N., Sidenna, M., Zayed, H. (2020). Dysregulation of signaling pathways due to differentially expressed genes from the B-Cell transcriptomes of systemic lupus erythematosus patients-A bioinformatics approach. Frontiers in Bioengineering and Biotechnology, 8, 276. [CrossRef]
12. 12. Mitchell, K.A., Zingone, A., Toulabi, L., Boeckelman, J., Ryan, B.M. (2017). Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23(23), 7412-7425. [CrossRef]
13. 13. Mao, Y., Xue, P., Li, L., Xu, P., Cai, Y., Chu, X., Jiang, P., Zhu, S. (2019). Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA gene pairs in small cell lung cancer. Molecular Medicine Reports, 20(3), 2199-2208. [CrossRef]
14. 14. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research, 13(11), 2498-2504. [CrossRef]
15. 15. Wagner, P.D., Verma, M., Srivastava, S. (2004). Challenges for biomarkers in cancer detection. Annals of the New York Academy of Sciences, 1022, 9-16. [CrossRef]
16. 16. Liang, G., Meng, W., Huang, X., Zhu, W., Yin, C., Wang, C., Fassan, M., Yu, Y., Kudo, M., Xiao, S., Zhao, C., Zou, P., Wang, Y., Li, X., Croce, C.M., Cui, R. (2020). miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 117(8), 4347-4357. [CrossRef]
17. 17. Hekmatshoar, Y., Rahbar Saadat, Y., Ozkan, T., Bozkurt, S., Karadag Gurel, A. (2024). Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: A Bioinformatics Study. Nucleosides, Nucleotides & Nucleic Acids, 43(7), 664-684. [CrossRef]
18. 18. Karadağ Gürel, A., Gürel, S. (2022). To detect potential pathways and target genes in infantile Pompe patients using computational analysis. BioImpacts : BI, 12(2), 89-105. [CrossRef]
19. 19. Karadağ Gürel, A., Gürel, S. (2022). Identification of novel potential molecular targets associated with pediatric septic shock by integrated bioinformatics analysis and validation of in vitro septic shock model: Identifies hub genes associated with pediatric septic shock. Journal of Surgery and Medicine, 6(12), 932-938. [CrossRef]
20. 20. Karadağ, A, Gürel S (2022). Pediatrik obezite ile ilişkili anahtar genlerin ve yolakların tanımlanması. Ege Tıp Bilimleri Dergisi, 5(2), 51-57. [CrossRef]
21. 21. Redin, E., Sridhar, H., Zhan, Y.A., Pereira Mello, B., Zhong, H., Durani, V., Sabet, A., Manoj, P., Linkov, I., Qiu, J., Koche, R.,P., de Stanchina, E., Astorkia, M., Betel, D., Quintanal-Villalonga, A., Rudin, C.M. (2024). SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Journal of Hematology and Oncology, 17, 58. [CrossRef]
22. 22. Zhu, Y., Wang, Z., Li, Y., Peng, H., Liu, J., Zhang, J., Xiao, X. (2023). The role of CREBBP/EP300 and its therapeutic implications in hematological malignancies. Cancers, 15(4), 1219. [CrossRef]
23. 23. Aseervatham, J. (2022). Interactions between 14-3-3 proteins and actin cytoskeleton and its regulation by micrornas and long non-coding rnas in cancer. Endocrines, 3(4), 665-702. [CrossRef]
24. 24. Gürel, S. (2019). Respiratory distress in newborn. Ege Tıp Bilimleri Dergisi, 2(1), 38-41. [CrossRef]
25. 25. Wang, P., Song, L., Ge, H., Jin, P., Jiang, Y., Hu, W., Geng, N. (2014). Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. OncoTargets and Therapy, 7, 1761-17688. [CrossRef]
26. 26. Tan, A.C. (2020). Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thoracic Cancer, 11(3), 511-518. [CrossRef]
27. 27. Alsharoh, H., Chiroi, P., Isachesku, E., Tanasa, R.A., Pop, O.L., Pirlog, R., Berindan-Neagoe, I. (2024). Personalizing therapy outcomes through mitogen-activated protein kinase pathway inhibition in non-small cell lung cancer. Biomedicines, 12(7), 1489. [CrossRef]
28. 28. Li, Z.H., Li, J.Y., Zhu, Y.J., Dai, L., Wu, Z.T., Nong, J.S., Zhuo, T., Li, F.L., He, L.Y., Liang, H.H., Zang, F.L., Wang, Y.Y., Chen, M.W., Huang, W.J., Cao, J.B. (2023). Analysis of nucleoporin 107 overexpression and its association with prognosis and immune infiltration in lung adenocarcinoma by bioinformatics methods. International Journal of General Medicine, 2023:16, 5449-5465. [CrossRef]
29. 29. Abel, H.J., Al-Kateb, H., Cottrell, C.E., Bredemeyer, A.J., Colin, C.P., Grossmann, A.H., Wallander, M.L., Pfeifer, J.D., Lockwood, C.M., Duncavage, E.J. (2014). Detection of gene rearrangements in targeted clinical next-generation sequencing. The Journal of Molecular Diagnostics, 16(4), 405-417. [CrossRef]